News

GSK's Q1 2025 earnings will reveal progress in specialty medicines amid regulatory headwinds. Learn what to watch when the ...
Q1 2025 Earnings Conference Call April 30, 2025 7:00 AM ETCompany ParticipantsConstantin Fest - Head of IREmma Walmsley - CEOLuke Miels ...
It offers a cure rate of around 90 per cent and, for some patients, comes with far milder side effects than peginterferon-based regimens ... efficacious. The chart below shows that these economic ...
A cross-sectional analysis shows that long-acting antiretroviral therapy sustains viral suppression regardless of initial ...
Persons initiating nPEP should be informed that preexposure prophylaxis (PrEP) can reduce their risk for acquiring HIV in the case ... for testing and nPEP regimens for persons exposed who have ...
Updated recommendations for antiretroviral nonoccupational postexposure prophylaxis (nPEP) for HIV have been published in the ...
As the Trump administration slashes funding for HIV-related research and infrastructure, Gilead, Immunocore and more are ...
Historically, managing HIV has required a lifelong commitment to daily oral antiretroviral therapy (ART). These regimens often involve multiple drugs from different classes, such as nucleoside ...
A panelist discusses how the new doravirine and islatravir combination offers an alternative to integrase inhibitor-based ...